Amicus Expands Rare Disease Pipeline with Scioderm Acquisition
By Heather Cartwright & Hardik Mewada
Pharma Deals Review: Vol 2015 Issue 9 (Table of Contents)
Published: 30 Sep-2015
DOI: 10.3833/pdr.v2015.i9.2123 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move to strengthen its pipeline of therapeutics for orphan diseases, Amicus Therapeutics has agreed to acquire privately held Scioderm for US$229 M upfront plus up to US$618 M contingent on the attainment of certain development and sales milestones...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS